Updated Jul 16, 2026
Dowden Nathan J has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $426K.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-04 | TRDA | Entrada Therapeutics, Inc. | S — Open-market sale | 15.0K | $15.33 | $230K |
| 2026-05-04 | TRDA | Entrada Therapeutics, Inc. | M — Option exercise | 15.0K | $1.74 | $26K |
| 2026-03-11 | TRDA | Entrada Therapeutics, Inc. | S — Open-market sale [10b5-1] | 11.9K | $13.05 | $155K |
| 2026-03-11 | TRDA | Entrada Therapeutics, Inc. | S — Open-market sale [10b5-1] | 3.1K | $13.02 | $41K |
| 2026-03-03 | TRDA | Entrada Therapeutics, Inc. | F — Tax withholding / forfeiture | 14.0K | $11.76 | $165K |
| 2026-03-03 | TRDA | Entrada Therapeutics, Inc. | F — Tax withholding / forfeiture | 7.2K | $11.66 | $84K |
| 2026-03-03 | TRDA | Entrada Therapeutics, Inc. | A — Grant or award | 55.8K | $0.00 | |
| 2025-09-02 | TRDA | Entrada Therapeutics, Inc. | F — Tax withholding / forfeiture | 1.7K | $5.43 | $9K |
Dowden Nathan J is a corporate insider — currently tracked as President & COO of Entrada Therapeutics, Inc. (TRDA). InsiderAlpha tracks every SEC Form 4 filing in real time.
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($426K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Dowden Nathan J profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.